Selective estrogen receptor modulation: The search for an ideal hormonal therapy for breast cancer

Cancer Investigation

Volumn 19, Issue 6, 2001, Pages 649-659

  Dhingra, K ^a  

^a HOFFMANN LA ROCHE INC   (United States)

Author keywords

Faslodex; Raloxifene; SERM; Steroid receptor; Transcription regulators

Indexed keywords

1,1,2 TRIPHENYLETHYLENE DERIVATIVE; 4 [4 METHYL 2 [4 [2 (1 PIPERIDINYL)ETHOXY]PHENYL] 7 PIVALOYLOXY 2H 1 BENZOPYRAN 3 YLPHENYL] PIVALATE; AMINOGLUTETHIMIDE; ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; ARZOXIFENE; DROLOXIFENE; ESTROGEN RECEPTOR; EXEMESTANE; FULVESTRANT; GONADORELIN AGONIST; GOSERELIN; IDOXIFENE; LASOFOXIFENE; LETROZOLE; LEUPRORELIN; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE; UNCLASSIFIED DRUG; VORAZOLE;

ALZHEIMER DISEASE; ARTICLE; BIOSYNTHESIS; BREAST CANCER; CANCER CELL; CANCER INVASION; CANCER RECURRENCE; CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; ENDOMETRIOSIS; ENDOMETRIUM HYPERPLASIA; ESTROGEN SYNTHESIS; FRACTURE; HORMONAL REGULATION; HORMONAL THERAPY; HOT FLUSH; HUMAN; NONHUMAN; PATHOGENESIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT PLANNING; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DRUG DESIGN; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; RALOXIFENE; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 0034926060     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-100104293     Document Type: Article

References (67)

1. Epidemiology of susceptibility to breast cancer
2. N-Ni-trosomethylurea as a mammary gland carcinogen in rats
3. Use of tamoxifen for breast cancer: Twenty-eight years later
4. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer
5. A phase III comparison of two toremiphene doses to tamoxifen in postmenopausal women with advanced breast cancer
6. Hormonal treatment for metastatic breast cancer: An Eastern cooperative oncology group phase III trial comparing aminoglutethimide to tamoxifen
7. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomised trials
8. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
9. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomized women
10. Interim analysis of the incidence of breast cancer in the royal Marsden hospital tamoxifen randomised chemoprevention trial
11. Is tamoxifen effective in prevention of breast cancer?
12. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women
13. Coronary heart disease mortality and adjuvant tamoxifen therapy
14. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen
15. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14
16. Endometrial thickness in tamoxifen-treated patients: Correlation with clinical and pathologic findings
17. Transvaginal sonographic and hysteroscopic findings in postmenopausal women receiving tamoxifen
18. Tamoxifen and the endometrium: Findings of pelvic ultrasound examination and endometrial biopsy in asymptomatic breast cancer patients
19. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial
20. Adjuvant tamoxifen in early-stage breast cancer: Effects on intercurrent morbidity and mortality
21. Tamoxifen-associated eye disease: A review
22. Induction of covalent DNA adducts in rodents by tamoxifen
23. Effects of chronic administration of tamoxifen and toremifene on DNA adducts in rat liver, kidney, and uterus
24. Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients
25. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer
26. Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors
27. Prevalence of estrogen receptor variant messenger RNAs in human breast cancer
28. Multiple splicing variants of the estrogen receptor are present in individual human breast tumors
29. Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer
30. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration
31. Human breast cancer in the athymic nude mouse: Cytostatic effects of long-term antiestrogen therapy
32. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors
33. Identification of estrogenic tamoxifen metabolite(s) in tamoxifen-resistant human breast tumors
34. Investigation of the mechanism of tamoxifen-stimulated breast tumor growth with nonisomerizable analogues of tamoxifen and metabolites
35. Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer
36. Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity
37. Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance
38. Type I IGF receptor and acquired tamoxifen resistance in oestrogen-responsive human breast cancer cells
39. Oestrogen directly stimulates growth factor signal transduction pathways in human breast cancer cells
40. Influence of droloxifene on metastatic breast cancer as first-line endocrine treatment
41. Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients
42. Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer
43. Effect of the high-affinity estrogen receptor ligand ICI 182780 on the rat tibia
44. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
45. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene - Results from a 3-year randomized clinical trial
46. The effect of raloxifene on risk of breast cancer in postmenopausal women - Results from the MORE Trial
47. The antitumor action of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model
48. Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels
49. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women
50. LY353381.HCI: A novel raloxifene analog with improved SERM potency and efficacy in vivo
51. EM-800, a novel antiestrogen, acts as a pure antagonist of the transcriptional functions of estrogen receptors α and β
52. Prevention of development of dimethylbenz(a)anthracene (DMBA)-induced mammary tumors in the rat by the new nonsteroidal antiestrogen EM-800 (SCH57050)
53. Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene
54. Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone serum cholesterol, uterus, and body composition in rat models
55. Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens
56. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer
57. The human estrogen receptor has two independent nonacidic transcriptional activation functions
58. Identification of a third autonomous activation domain within the human estrogen receptor
59. Role of the two activating domains of the estrogen receptor in the cell-type and promoter-context dependent agonist activity of the antiestrogen 4-hydroxytamoxifen
60. Molecular basis of agonism and antagonism in the oestrogen receptor
61. Molecular determinants of tissue selectivity in estrogen receptor modulators
62. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT
63. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen
64. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer
65. Differential activation of estrogen receptors ERα and ERβ at AP1 Sites
66. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
67. Antiestrogens - Tamoxifen, SERMs and beyond